UNITED STATES
NUCLEAR REGULATORY COMMISSION
REGION I
475 ALLENDALE ROAD
KING OF PRUSSIA, PENNSYLVANIA 19406-1415

August 15, 2007

Docket No. 03001274 License No. 06-08544-01
Control No. 140825

Keith A. Hovan
Chief Operation Officer
Danbury Hospital
24 Hospital Avenue
Danbury, CT 06810

SUBJECT: DANBURY HOSPITAL, LICENSE AMENDMENT, CONTROL NO. 140825

Dear Mr. Hovan:

This refers to your license amendment request dated July 2, 2007. Enclosed with this letter is the amended license.

Please review the enclosed document carefully and be sure that you understand and fully implement all the conditions incorporated into the amended license. If there are any errors or questions, please notify the U.S. Nuclear Regulatory Commission, Region I Office, Licensing Assistance Team, (610) 337-5239, so that we can provide appropriate corrections and answers.

An environmental assessment for this action is not required, since this action is categorically excluded under 10 CFR 51.22(c)(14).

Current NRC regulations and guidance are included on the NRC's website at www.nrc.gov; select **Nuclear Materials; Medical, Academic, and Industrial Uses of Nuclear Material;** then **Regulations, Guidance, and Communications.** You may also obtain these documents by contacting the Government Printing Office (GPO) toll-free at 1-866-512-1800. The GPO is open from 7:00 a.m. to 8:00 p.m. EST, Monday through Friday (except Federal holidays).

Thank you for your cooperation.

Sincerely,

***Original signed by Shirley Xu***

Shirley Xu
Health Physicist
Medical Branch
Division of Nuclear Materials Safety

Enclosure:
Amendment No. 85

cc:
Vladimir Monastyrenko, Ph.D., Radiation Safety Officer

DOCUMENT NAME: C:\FileNet\ML072270287.wpd

**SUNSI Review Complete:** SXu
After declaring this document "An Official Agency Record" it **will** be released to the Public.

**To receive a copy of this document, indicate in the box:** "**C**" = Copy w/o attach/encl "**E**" = Copy w/ attach/encl "**N**" = No copy

| OFFICE | DNMS/RI | N | DNMS/RI | | DNMS/RI | | | |
|---|---|---|---|---|---|---|---|---|
| NAME | SXu/SSX | | | | | | | |
| DATE | 8/15/07 | | | | | | | |

OFFICIAL RECORD COPY

Amendment No. 85

# MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 39, 40, and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

| Licensee | In accordance with the application dated July 2, 2007, |
|---|---|
| 1. Danbury Hospital | 3. License number 06-08544-01 is amended in its entirety to read as follows: |
| 2. 24 Hospital Avenue<br>Danbury, CT 06810 | 4. Expiration date November 30, 2015 |
| | 5. Docket No. 030-01274<br>Reference No. |

| 6. Byproduct, source, and/or special nuclear material | 7. Chemical and/or physical form | 8. Maximum amount that licensee may possess at any one time under this license |
|---|---|---|
| A. Any byproduct material permitted by 10 CFR 35.100 | A. Any | A. As needed |
| B. Any byproduct material permitted by 10 CFR 35.200 | B. Any | B. As needed |
| C. Any byproduct material permitted by 10 CFR 35.300 | C. Any | C. 1300 millicuries |
| D. Any byproduct material permitted by 10 CFR 35.400 | D. Sealed Sources (AEA Technology Model CDC.T1 [marketed as Amersham Model CDC.T1], Bard Brachytherapy, Inc Model STM 1251, and 3M Model 6500/6520) | D. 2000 millicuries |
| E. Any byproduct material permitted by 10 CFR 31.11 | E. Prepackaged Kits | E. 1 millicurie |
| F. Cesium 137 | F. Sealed Source (AEA Technology, PLC Model 77302) | F. 200 millicuries |

9. Authorized use:

A. Any uptake, dilution and excretion study permitted by 10 CFR 35.100.
B. Any imaging and localization study permitted by 10 CFR 35.200.

**MATERIALS LICENSE**
**SUPPLEMENTARY SHEET**

License Number
06-08544-01

Docket or Reference Number
030-01274

Amendment No. 85

C. Any diagnostic study or therapy procedure permitted by 10 CFR 35.300.
D. Any manual brachytherapy procedure permitted by 10 CFR 35.400.
E. In vitro studies.
F. For use in a Tech-Ops Model 77302 for calibrations and checking of licensee's survey instruments.

CONDITIONS

10. A. Licensed material may be used or stored only at the licensee's facility located at 24 Hospital Avenue, Danbury, Connecticut;

    B. Licensed material listed in Item 6.A. and 6.B. may be used or stored only at the licensee's facility located at Cardiovascular Diagnostic Center (Danbury Hospital), 22 Old Waterbury Road, Suite 107, Southbury, Connecticut.

11. The Radiation Safety Officer for this license is Vladimir Monastyrenko, Ph.D.

12. Licensed material is only authorized for use by, or under the supervision of:

    A. Individuals permitted to work as an authorized user, and/or authorized medical physicist in accordance with 10 CFR 35.13 and 35.14.

    B. The following individuals are authorized users for medical use as indicated:

| Authorized Users | Material and Use |
|---|---|
| Joseph J. Belsky, M.D. | 35.100; 35.200; In vitro studies<br>Oral administration of sodium iodide iodine-131 for imaging and localization studies and treatment of hyperthyroidism and cardiac dysfunction |
| Ramon N. Kranwinkel, M.D. | 35.100; 35.200; In vitro studies |
| Shiv Gupta, M.D. | 35.100; 35.200; 35.300; In vitro studies |
| Jonathan Alexander, M.D. | 35.100; 35.200 |
| Andrew M. Keller, M.D. | 35.100; 35.200 |
| John A. Spera, M.D. | 35.300; 35.400 |
| William D. Johns, M.D. | 35.100; 35.200; 35.300; In vitro studies |
| Noah A. Taylor, M.D. | 35.300; 35.400 |
| Robert Savino, M.D. | Oral administration of sodium iodide iodine-131 |

**MATERIALS LICENSE**
**SUPPLEMENTARY SHEET**

License Number
06-08544-01

Docket or Reference Number
030-01274

Amendment No. 85

| Authorized Users | Material and Use |
|---|---|
| Susan Mani, M.D. | 35.100; 35.200 |

C. The following individuals are authorized users for non-medical uses as indicated:

| Users | Material and Use |
|---|---|
| Ian Crooks, M.Sc. | Cesium-137 for calibration of instruments |
| Vladimir Monastyrenko, Ph.D. | Cesium-137 for calibration of instruments |

13. In addition to the possession limits in Item 8, the licensee shall further restrict the possession of licensed material to quantities below the minimum limit specified in 10 CFR 30.35(d) for establishing decommissioning financial assurance.

14. For sealed sources not associated with 10 CFR Part 35 use, the following conditions apply:

A. Sealed sources shall be tested for leakage and/or contamination at intervals not to exceed six months or at the intervals specified in the certificate of registration issued by the U.S. Nuclear Regulatory Commission under 10 CFR 32.210 or under equivalent regulations of an Agreement State.

B. In the absence of a certificate from a transferor indicating that a leak test has been made within the intervals specified in the certificate of registration issued by the U.S. Nuclear Regulatory Commission under 10 CFR 32.210 or under equivalent regulations of an Agreement State, prior to the transfer, a sealed source received from another person shall not be put into use until tested and the test results received.

C. Sealed sources need not be tested if they are in storage and are not being used; however, when they are removed from storage for use or transferred to another person and have not been tested within the required leak test interval, they shall be tested before use or transfer. No sealed source shall be stored for a period of more than 10 years without being tested for leakage and/or contamination.

D. The leak test shall be capable of detecting the presence of 0.005 microcurie (185 becquerels) of radioactive material on the test sample. If the test reveals the presence of 0.005 microcurie (185 becquerels) or more of removable contamination, a report shall be filed with the U.S. Nuclear Regulatory Commission in accordance with 10 CFR 30.50(c)(2), and the source shall be removed immediately from service and decontaminated, repaired, or disposed of in accordance with Commission regulations.

E. Tests for leakage and/or contamination, including leak test sample collection and analysis, shall be performed by the licensee or by other persons specifically licensed by the U.S. Nuclear Regulatory Commission or an Agreement State to perform such services.

**MATERIALS LICENSE**
**SUPPLEMENTARY SHEET**

License Number
06-08544-01

Docket or Reference Number
030-01274

Amendment No. 85

F. Records of leak test results shall be kept in units of microcuries and shall be maintained for 5 years.

15. The licensee shall conduct a physical inventory every six months, or at other intervals approved by the U.S. Nuclear Regulatory Commission, to account for all sources and/or devices received and possessed under the license. Records of inventories shall be maintained for 5 years from the date of each inventory and shall include the radionuclides, quantities, manufacturer's name and model numbers, and the date of the inventory.

16. Sealed sources or detector cells containing licensed material shall not be opened or sources removed from source holders by the licensee.

17. The licensee is authorized to transport licensed material in accordance with the provisions of 10 CFR Part 71, "Packaging and Transportation of Radioactive Material."

18. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.

A. Application dated June 22, 2005 [ML051920264]
B. Letter dated August 26, 2005 [ML052550358]
C. Letter dated November 02, 2005 [ML053080085]
D. Letter dated February 2, 2006 [ML060580674]
E. Letter dated March 10, 2006 [ML060740210]
F. Letter dated July 2, 2007 [ML072050095]

For the U.S. Nuclear Regulatory Commission

Date August 15, 2007

By ***Original signed by Shirley Xu***

Shirley Xu
Medical Branch
Division of Nuclear Materials Safety
Region I
King of Prussia, Pennsylvania 19406